Andy Cohen TRT: Hypothesized Full Protocol Based on Public Statements

What Andy Cohen Has Said About Hormone Therapy

Andy Cohen has been more candid than most public figures about using HRT. On his SiriusXM program "Radio Andy," Cohen discussed feeling the effects of hormonal changes as he aged into his fifties and mentioned working with a physician to address them. He has referenced feeling "better than ever" after starting hormone therapy, a phrase consistent with the symptom relief men typically report within 3 to 6 months of initiating TRT.

The Public Record

Cohen has not released lab values or prescription details. What the public record contains is the following: he acknowledged discussing declining energy, changes in body composition, and libido-related concerns with a doctor. He confirmed starting some form of HRT. He has not named a specific drug, dose, or clinic.

That is the boundary of confirmed fact. Everything in the protocol section below is labeled inference, built from his demographic data and current published guidelines.

Why Public Figures Discussing TRT Matters Clinically

Public acknowledgment by recognizable figures drives search volume and, more consequentially, clinic visits. A 2021 analysis in the Journal of Sexual Medicine found that online celebrity mentions of testosterone therapy correlated with a measurable uptick in clinic inquiries in the 30-day window following coverage (1). That effect is neither inherently good nor bad. The clinical value depends entirely on whether the subsequent medical evaluation is thorough.

Who Is a Candidate for TRT? The Guideline Framework

Before constructing any hypothesized protocol, it is worth establishing what guidelines actually require for TRT eligibility. Cohen's public statements are consistent with the symptom profile that guidelines use to identify candidates.

Endocrine Society 2018 Criteria

The Endocrine Society's 2018 Clinical Practice Guideline recommends TRT for men who have both classic symptoms of androgen deficiency AND unambiguously low serum testosterone levels confirmed on at least two morning measurements (2). Classic symptoms include decreased libido, erectile dysfunction, reduced energy, depressed mood, decreased muscle mass, and increased body fat.

The guideline states: "We suggest testosterone therapy for men with hypogonadism to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density." (2)

Diagnostic Thresholds

Total testosterone below 300 ng/dL on two morning draws is the most commonly cited diagnostic threshold, though the American Urological Association's 2018 guideline uses a threshold of <300 ng/dL and notes that clinical judgment applies in men with values between 300 and 400 ng/dL who carry significant symptoms (3). Symptoms alone, without confirmed biochemical hypogonadism, are not sufficient under either guideline.

Cohen's Demographic Context

At 57, Cohen sits in an age range where the prevalence of biochemical hypogonadism (total testosterone <300 ng/dL) is approximately 20 to 30 percent according to the Massachusetts Male Aging Study longitudinal data (4). Testosterone declines at roughly 1 to 2 percent per year after age 30, so a man who was in the lower half of the reference range at 35 may reach diagnostic hypogonadism by his early fifties.

Hypothesized Protocol: What Cohen Might Actually Be Taking

This section is entirely inferential. The protocol below is constructed from three inputs: Cohen's public symptom descriptions, his age and sex, and current prescribing norms documented in peer-reviewed literature and FDA-approved labeling. No source with direct knowledge of Cohen's care has contributed to this section.

Testosterone Formulation Options

There are four delivery routes in widespread clinical use in the United States.

Intramuscular (IM) injectable testosterone cypionate or enanthate. The FDA-approved dosing range for testosterone cypionate is 50 to 400 mg every 2 to 4 weeks, though most contemporary TRT clinicians use 100 mg weekly or 200 mg every two weeks to minimize peak-to-trough variability (5). This remains the most cost-effective route and is the most frequently prescribed formulation in U.S. Men's health clinics.

Transdermal testosterone gel (1.62% or 2%). AndroGel 1.62% (testosterone 20.25 mg per actuation) is applied daily to the upper arms or shoulders. In a key registration trial, daily AndroGel 1.62% normalized testosterone in 72 to 77 percent of hypogonadal men at 12 weeks (6). Gels suit men who prefer to avoid injections and have low transfer-risk to partners or children.

Subcutaneous pellets. Testosterone pellets (Testopel) are implanted under the skin every 3 to 6 months. They deliver steady-state testosterone without weekly administration. Some concierge and private clinics favor pellets for patients with demanding travel schedules, which describes Cohen's professional profile.

Transdermal patch (Androderm). Less commonly prescribed now due to skin irritation rates of approximately 37 percent in registration studies, but still FDA-approved and clinically available (7).

Most Likely Formulation for Cohen's Profile

A 57-year-old with a demanding broadcast schedule, access to concierge-level medical care, and confirmed HRT use is statistically most likely on either weekly subcutaneous testosterone cypionate self-injection (now the dominant form in men's health telehealth, typically 80 to 120 mg weekly) or testosterone pellets placed every 4 to 5 months. Injectable cypionate is favored here as the base inference because it is reversible, easily dose-adjusted, and consistent with the kind of actively monitored therapy a medically supervised patient would receive.

Hypothesized base dose: Testosterone cypionate 100 mg subcutaneously once weekly. This produces mean steady-state total testosterone in the 500 to 650 ng/dL range in most men, comfortably within the mid-normal reference range of 300 to 1000 ng/dL (8).

Ancillary Medications Commonly Co-Prescribed

TRT does not exist in isolation. Three ancillary agents are routinely co-prescribed depending on labs and clinical response.

Anastrozole (aromatase inhibitor). Testosterone converts to estradiol via aromatase, and some men on TRT develop symptomatic estrogen excess (gynecomastia, water retention, mood changes). Anastrozole 0.25 mg to 0.5 mg twice weekly is a common prescription to keep estradiol in the 20 to 30 pg/mL range (9). Whether Cohen needs this depends on his aromatization rate and body fat percentage, which are unknown. It is included in the hypothesized protocol as a conditional agent, meaning it may or may not be prescribed.

Human chorionic gonadotropin (hCG). Men on exogenous testosterone suppress their own LH and FSH, which causes testicular atrophy and eliminates endogenous testosterone production. HCG (500 to 1,000 IU subcutaneously 2 to 3 times per week) mimics LH and maintains intratesticular testosterone and testicular volume. Many clinicians prescribe it routinely for men who are not actively trying to conceive but wish to preserve gonadal function and volume (10). Cohen's public profile includes fatherhood via surrogate (two sons), and while he is not known to be pursuing additional children, hCG is a reasonable inclusion.

Vitamin D3 and zinc. Not prescription-only, but both micronutrients are commonly co-supplemented in men's health protocols. Serum 25-hydroxyvitamin D below 20 ng/mL is independently associated with lower total testosterone in population data (11). Most TRT clinicians check 25-OH vitamin D and prescribe 2,000 to 5,000 IU daily if deficient.

Monitoring Schedule

The Endocrine Society guideline recommends checking hematocrit, total testosterone, and PSA at 3 to 6 months after initiation and then annually (2). A typical monitoring panel includes:

• Total and free testosterone (target: 400 to 700 ng/dL total)
• Estradiol (sensitive assay, target: 20 to 30 pg/mL)
• Hematocrit (target: <54%, as polycythemia is the most common adverse effect of TRT)
• PSA (baseline and annual, given age)
• Complete metabolic panel and lipid panel
• LH and FSH (suppressed on therapy, used as compliance/adherence marker)

Clinical Evidence: What TRT Actually Does

Any celebrity protocol discussion is incomplete without a grounded review of what testosterone therapy demonstrably achieves versus what it does not.

Body Composition

The TRAVERSE trial (N=5,246, median age 63.5, mean follow-up 33 months) showed that testosterone therapy in men with hypogonadism and elevated cardiovascular risk produced significant improvements in lean mass and reductions in fat mass compared to placebo, without increasing the rate of major adverse cardiovascular events at 3 years of follow-up (12). This was a meaningful safety reassurance after earlier concern from the 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial, which was stopped early due to cardiovascular signals in a frail elderly population not representative of the broader TRT candidate pool (13).

Sexual Function and Quality of Life

The Testosterone Trials (TTrials), a coordinated set of seven double-blind placebo-controlled trials in 788 men aged 65 or older with total testosterone <275 ng/dL, found that testosterone treatment for one year improved sexual desire (mean International Index of Erectile Function score increase of 2.64 points vs. Placebo), physical function, and mood, but did not significantly reduce depressive symptoms as a primary endpoint (14). The sexual benefit was consistent across age groups within the trial.

Energy and Mood

Men in the TTrials reported statistically significant improvements in energy-related quality of life on the FACT-G scale. The effect size was modest (mean difference 0.9 points on a 28-point scale, P<0.001 in the sexual function sub-trial), which means TRT is not a cure for fatigue but may address the fraction attributable to androgen deficiency (14).

What TRT Does Not Do

TRT does not reliably produce dramatic physique changes in the absence of resistance training and adequate protein intake. A 2001 NEJM study by Bhasin et al. (N=61) showed that testosterone supraphysiologic doses (600 mg weekly, far above replacement dosing) plus resistance exercise produced greater muscle gains than testosterone alone, confirming that exercise is not optional if body composition is a goal (15).

Risks, Contraindications, and Cautions at Age 57

Cardiovascular Risk

The TRAVERSE trial largely resolved the cardiovascular uncertainty that surrounded TRT after 2013, showing no increase in MACE (major adverse cardiovascular events) at 33 months in men with pre-existing cardiovascular disease or high risk. The rate of MACE was 7.0% in the testosterone group vs. 7.3% in placebo (non-inferiority margin met, P<0.001) (12).

Polycythemia

The most common laboratory adverse effect of TRT is erythrocytosis (elevated hematocrit). In the TRAVERSE trial, hematocrit exceeded 54% in 5.7% of testosterone-treated men vs. 1.0% of placebo (12). Therapeutic phlebotomy or dose reduction resolves this in most cases. All TRT patients should have hematocrit checked at 3 months and every 6 to 12 months thereafter.

Prostate Safety

Current guidelines do not list a history of mild to moderate lower urinary tract symptoms as an absolute contraindication to TRT, but active or suspected prostate cancer is. PSA should be checked at baseline, at 3 to 6 months, and annually in men over 40 on TRT (2).

Fertility

Exogenous testosterone suppresses spermatogenesis by reducing FSH. Men who wish to preserve fertility should use hCG-based protocols or consider alternatives such as clomiphene citrate rather than exogenous testosterone (16). Cohen has two children and has not publicly indicated plans for additional biological children, but this consideration is standard in any informed consent process.

How a HealthRX Physician Would Evaluate a Similar Patient

A 57-year-old male presenting with the symptom cluster Cohen has described (energy decline, body composition changes, decreased libido) would undergo the following workup at HealthRX before any prescription is written.

Initial Lab Panel

• Total testosterone (two morning draws, ideally between 7 and 10 a.m., at least one week apart)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to classify hypogonadism as primary or secondary)
• Estradiol (sensitive LC-MS/MS assay)
• SHBG (sex hormone-binding globulin)
• Complete blood count with differential (baseline hematocrit)
• Comprehensive metabolic panel
• Lipid panel
• PSA
• 25-hydroxyvitamin D
• Prolactin (to rule out pituitary adenoma as cause of secondary hypogonadism)
• TSH (thyroid dysfunction mimics many hypogonadism symptoms)

Clinical Decision Threshold

Treatment would be offered only if at least two of the following are met: total testosterone <300 ng/dL on two draws, free testosterone below the laboratory reference lower limit, and a validated symptom score (ADAM questionnaire positive response on questions 1 or 7, or an AMS scale score above 37) consistent with androgen deficiency.

A man with a total testosterone of 350 ng/dL but significant symptom burden would be discussed in a shared decision-making framework, noting that the AUA guideline acknowledges clinical judgment in the 300 to 400 ng/dL gray zone (3).

Summary of the Hypothesized Andy Cohen TRT Protocol

The table below collects the full hypothesized protocol for reference. Every element is inference based on demographic profile and clinical norms, not confirmed information.

| Agent | Hypothesized Dose | Route | Frequency | Notes | |---|---|---|---|---| | Testosterone cypionate | 100 mg | Subcutaneous injection | Once weekly | Core hormone; dose adjusted per labs | | Anastrozole | 0.25 to 0.5 mg | Oral | Twice weekly | Conditional on estradiol labs | | hCG | 500 IU | Subcutaneous injection | 2 to 3x per week | Preserves testicular function | | Vitamin D3 | 2,000 to 5,000 IU | Oral | Daily | If 25-OH-D <30 ng/mL | | Zinc bisglycinate | 25 to 30 mg | Oral | Daily | Cofactor for testosterone synthesis |

Lab monitoring: Total testosterone, estradiol, hematocrit, PSA, and CMP at 3 months, then every 6 months once stable.